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VEGFAbstract Aim of the work: To evaluate the cardiovascular ﬁndings in Behc¸et’s disease (BD) and
assess the levels of vascular endothelial growth factor (VEGF) to study its relation to the extent
of cardiovascular involvement.
Patients and methods: Thirty patients with BD were included in the study; 24 males and 6
females. Twenty age and sex matched healthy volunteers served as controls. All subjects were
assessed clinically. The cardiovascular disorders were assessed by clinical examination, chest
X-ray, electrocardiography, echocardiography, and lower extremity Doppler ultrasonography. Fur-
ther investigations were performed for selected patients (stress ECG, chest computed tomography
and coronary angiography). Routine laboratory investigations and serum level of VEGF were per-
formed. Disease activity was assessed using Behc¸et’s Disease Current Activity Form (BDCAF).
Results: 40% of our patients had vascular complications, where 25% had only DVT, 16.7% had
only large veins thrombosis, 16.7% had both deep and large veins thrombosis, 16.7% patients had
both DVT and cardiac lesions, 10% showed arteritis with aneurysms. Cardiac involvement was
detected in 8 patients (26.7%), where 13.3% had mitral regurge, 3.3% had mitral valve prolapse,
3.3% had aortic regurge, 3.3% had tricuspid regurge, 3.3% had right ventricular thrombus with
132 A.B. Eldin, A. Ibrahimright bundle branch block and 3.3% had antro-septal myocardial infarction. Serum levels of VEGF
were signiﬁcantly higher (p< 0.001) in patients (301.2 ± 134.5 pg/ml) than in controls
(61.4 ± 52.5 pg/ml). The mean VEGF level signiﬁcantly correlated with the BDCAF.
Conclusions: Assessment of the cardiovascular system is advised in all patients with BD. The
association between VEGF and cardiovascular involvement suggests a role for VEGF in the cardio-
vascular etiopathogenesis in Behc¸et’s disease.
 2014 Production and hosting by Elsevier B.V. on behalf of Egyptian Society for Joint Diseases and
Arthritis.Open access under CC BY-NC-ND license.1. Introduction
Behc¸et’s disease (BD) is a systemic disorder of recurrent acute
inﬂammation characterized by major symptoms: aphthous ul-
cers, genital ulcers, uveitis and skin lesions. Involvement of
intestines, vessels and CNS system sometimes leads to poor
prognosis [1]. It is considered as a nonspeciﬁc systemic vascu-
litis of small and large vessels involving both venous and arte-
rial sides, [2] with particular systemic features including
thrombotic events. Venous thrombosis can be seen in any vein
with a thrombus sticky to the inﬂamed vessel wall. Arterial
involvement is seen less frequently and can result in true
and/or false aneurysms or less frequently a thrombotic occlu-
sion [3]. The precise pathogenic mechanism underlying the
thrombotic tendency in BD is still obscure, but vasculitic endo-
thelial cell injury and/or dysfunction which results from im-
mune-mediated inﬂammatory inﬁltrate with hypoﬁbrinolysis
have been suggested to play crucial roles [4].
Vascular endothelial growth factor (VEGF) is a glycopro-
tein with similarity to platelet derived growth factor. It is a po-
tent cytokine that modulates angiogenesis by acting as an
essential mitogen for vascular endothelial cells. Because VEGF
is a potent mitogen for dermal and ocular microvascular endo-
thelial cells, its expression may be important in the vascular
bed of Behcet’s patients [5].
Cardiac involvement is among themost life-threatening com-
plications in BD but its incidence and nature are not yet clearly
documented [6]. Mortality of this complication is relatively high
(around 20%). In addition cardiac involvement in BD can be
seen frequently without symptoms [7]. The spectrum of cardiac
disease, according to reported cases in the literature,may include
pericarditis, coronary artery stenosis or aneurysm, myocarditis,
cardiomyopathy, congestive heart failure, valvular pathology,
endocarditis, intracardiac thrombosis, and aneurysm of aorta
or its branches [8]. In this regard, it is of great importance to
delineate the cardiovascular involvement in BD [9].
The present study aimed at evaluation of the cardiovascular
ﬁndings in patients with Behcet’s disease and assessment of
their serum levels of vascular endothelial growth factor
(VEGF) in order to study its relation to the extent of cardio-
vascular involvement.
2. Patients and methods
Thirty Egyptian patients diagnosed as BD were included in
this study. All patients have fulﬁlled the International Study
Group criteria for Behc¸et’s disease, [10] randomly recruited
from the Ain Shams University Hospital internal medicine
department and rheumatology outpatient clinic between
December 2011 and December 2012. They were all free ofany cardiovascular symptoms. Twenty healthy age and sex
matched volunteers served as controls. A verbal consent was
obtained from all subjects participating in this study, after
explaining its nature. The study was approved by the Ain
Shams local ethics committee.
2.1. Exclusion criteria
Patients with evidence of pre-existing cardiac and/or vascular
affection due to diseases other than Behc¸et’s disease, together
with cases of diabetes mellitus were excluded from this study.
2.2. Clinical assessment
 Full history taking and clinical examination at time of
inclusion into the study, and this clinical assessment
included cardiac examination, dermatological examination
for all skin lesions and professional ocular examination.
The disease activity was assessed using Behc¸et’s Disease
Current Activity Form (BDCAF) score. Patients with BD
were categorized as active (total activity scoreP 5) or
inactive (total activity score < 5) [11].
2.3. Laboratory assessment
 Standard laboratory investigations were done including:
complete blood picture (CBC), Erythrocyte sedimentation
rate [ESR], C-reactive protein [CRP], kidney function
(BUN-serum creatinine), liver enzymes (AST-ALT), and
complete lipid proﬁle.
 VEGF levels in the serum were measured by enzyme-linked
immunosorbent assay (ELISA) using microtiter plates
coated by anti-human VEGF antibody (R&D systems,
Minneapolis, MN).
2.4. Cardiovascular evaluation
 Resting electrocardiogram (ECG).
 Chest X-ray.
 Trans-Thoracic Echocardiography (TTE).
 Vascular involvement was assessed by arterial and venous
Doppler ultrasound.
 Further in-depth investigations for selected patients who
had positive or suggestive ﬁndings for cardiac or major ves-
sel affection on clinical examination were also conducted
Table 1 Clinical characteristic of patients with Behc¸et’s
disease.
Clinical manifestations Number (30) Percent (%)
Oral ulcers 30 (100)
Genital ulcers 23 (76.7)
Eye lesions 12 (40)
Skin lesions 21 (70)
Positive pathergy test 10 (33.3)
Articular manifestation 11 (36.7)
Neurological manifestations 3 (10)
Vascular ﬁndings 12 (40)
Deep vein thrombosis (DVT) 7 (23.3)
Large vein thrombosis 4 (13.3)
Arterial aneurysm 3 (10)
Cardiac manifestations 8 (26.7)
Mitral regurge (MR) 4 (13.3)
Mitral valve prolapsed (MVP) 1 (3.3)
Aortic regurge (AR) 1 (3.3)
Tricuspid regurge (TR) 1 (3.3)
Antro-septal MI 1 (3.3)
RV Thrombus + RBBB 1 (3.3)
MI, myocardial infarction; RV, right ventricle; RBBB, right bundle
branch block.
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chest computed tomography (CT), and coronary
angiography.
Statistical methods: IBM SPSS statistics (V. 22.0, IBM
Corp., USA, 2013) was used for data analysis. Data were
expressed as Mean ± SD for quantitative parametric measures
in addition to Median Percentiles for quantitative non-para-
metric measures and both number and percentage for catego-
rized data.
The following tests were done:
1. Comparison between two independent mean groups for
parametric data using Student’s t test.
2. Comparison between two independent groups for non-
parametric data using the Wilcoxon Rank Sum test.
3. Ranked Spearman correlation test to study the possible
association between each two variables among each group
for non-parametric data.
4. Chi-square test to study the association between each 2
variables or comparison between 2 independent groups as
regards the categorized data.
5. Comparison between 2 proportions as regards univariant
categorized data.
The probability of error at 0.05 was considered signiﬁcant;
while at 0.01 and 0.001 are highly signiﬁcant.
3. Results
The present study included thirty Behcet’s disease (BD) pa-
tients (Group I) with an age ranging from 20 to 52 yr
(30.6 ± 9.36 years), and the male to female ratio was 4:1 (24
males and 6 females). Twenty age and sex matched healthy vol-
unteers served as controls (Group II). Their ages ranged from
19 to 47 yr (26.9 ± 8.38 years) with a male to female ratio 4:l
(16 males and 4 females).
The general features and clinical manifestations of the stud-
ied BD patients (Group I) are displayed in Table 1.
Twelve patients (40%) had vascular complications of the 12
patients with vascular involvement, 3 (25%) patients had only
DVT, 2 (16.7%) patients had only large vein thrombosis (SVC
and IVC), 2 (16.7%) patients had both deep and large veins
thrombosis, and 2 (16.7%) patients had both DVT and cardiac
lesions. Arterial events were evident in 3 patients (10%); arter-
itis associated with aneurysm formation {two patients (6.7%)
showed pulmonary artery aneurysms and one (3.3%) patient
had femoral artery aneurysm}.
Eight patients (26.7%) had cardiac involvement. There was
a high prevalence of mitral valve affection (5 patients-16.3%)
in the form of mitral regurge (4 patients-13.3%) and mitral
valve prolapsed (one patient-3.3%).Other cardiac complica-
tions were in the form of aortic regurge (one patient-3.3%)
NB: this patient had also mitral regurge, tricuspid regurge
(one patient-3.3%), antro-septal myocardial infarction (one
patient-3.3%), and right ventricular thrombus with right bun-
dle branch block (RBBB) (one patient-3.3%). This patient
with right ventricular thrombus and RBBB was treated with
oral anticoagulant, steroids, azathioprine and cyclosporine
therapy with complete resolution of the thrombus within
2 months.On comparing BD (Group I) with the controls (Group II)
the Hg, ESR, CRP, cholesterol, triglycerides, low density
lipoprotein (LDL-C) and serum creatinine levels in all patients
were signiﬁcantly higher than that of the controls (p< 0.001,
and/or p< 0. 01), while the serum level of high density lipo-
protein (HDL-C) in all patients was signiﬁcantly lower than
that of the controls (p< 0.001). The VEGF levels of the pa-
tients were highly signiﬁcantly higher than those of the healthy
controls (p< 0.001) (Table 2).
According to the presence or absence of cardiac and vascu-
lar manifestations BD patients (Group I) were further classi-
ﬁed into two subgroups:
 Group Ia includes the patients with cardio-vascular affec-
tion (10 patients had only vascular lesions, 6 patients had
only cardiac lesions, and 2 patients had both vascular and
cardiac lesions {total n= 18}).
 Group Ib includes the patients without cardio-vascular
affection (12 patients).
On comparing the subgroups; group Ia and group Ib as re-
gards the clinical manifestations of BD, genital ulcers and joint
affection were signiﬁcantly higher in Group Ia (88.9% vs 58%
and 50% vs 16.7%, respectively) (p< 0.05), while eye lesions
were signiﬁcantly higher in Group Ib (66.7% vs 22.2%)
(p< 0.05). (Table 3).
The patients’ age was signiﬁcantly higher in group Ia
(p< 0.001), while no signiﬁcant difference was found concern-
ing disease duration (p> 0.05).
The frequency of male sex was signiﬁcantly higher among
the patients of group Ia {16 (88.9%) males vs. 2 (11.1%) fe-
males}, than group Ib {8 (66.7) males vs. 4 (33.3%) females}
(p< 0.05). The BD activity score was also, signiﬁcantly higher
among the patients of group Ia (p< 0.01).
Serum levels of cholesterol, triglycerides, low density lipo-
protein (LDL-C) in the subgroup Ia patients were signiﬁcantly
Table 2 Comparison between Behcet’s disease patients and the controls as regards the age and the laboratory investigations.
Variables Mean ± SD Group I BD Patients (30) Group II Control (20) p-Value
Age (years) 30.6 ±9.37 26.9 ±8.39 >0.05 ns
Hg (gm/dl) 11.94 ±1.86 13.51 ±1.72 <0.01*
TLC (·103/mm3) 7.52 ±3.26 7.27 ±2.24 >0.05 ns
PLT (·103/mm3) 270.92 ±76.96 278.22 ±92.52 >0.05 ns
ESR (mm/h) 66.67 ±34.88 8.9 ±3.071 <0.001 **
CRP (mg/dl) 22.17 ±12.72 1.7 ±0.82 <0.001**
Cholesterol (mg/dl) 181.76 ±43.9 120.52 ±5.03 <0.001**
Triglycerides (mg/dl) 94.7 ±21.62 76.3 ±18.72 <0.01*
HDL-C (mg/dl) 33.4 ±11.93 85.3 ±16.99 <0.001**
LDL-C (mg/dl) 85.53 ±18.4 54.8 ±8.11 <0.001**
Serum creatinine (mg/dl) 0.95 ±0.22 0.76 ±0.28 <0.01*
AST (U/L) 31.28 ±20.84 27.33 ±22.36 >0.05 ns
ALT (U/L) 31.08 ±21.62 29.11 ±22.84 >0.05 ns
VEGF (pg/ml) 301.2 ±134.5 61.4 ±52.5 <0.001**
Hg, hemoglobin; TLC, total leukocytic count; PLT, platelets; CRP, C-reactive protein; HDL-C, high density lipoprotein cholesterol; LDL-C,
low density lipoprotein cholesterol; AST, aspartate transaminase, ALT, alanine transaminase; VEGF, vascular endothelial growth factor; ns,
non signiﬁcant.
* Signiﬁcant.
** Highly signiﬁcant.
Table 3 Comparison between Behcet’s disease patients’ subgroups as regards the clinical characteristic.
Manifestations number (%) Cardiovascular aﬀection (Group Ia) N= 18 No cardiac – vascular aﬀection (Group Ib) N = 12 p-Value
Oral ulcers 18 (100) 12 (100) –
Genital ulcers 16 (88.9) 7 (58) <0.05 S
Eye lesions 4 (22.2) 8 (66.7) <0.05 S
Cutaneous 14 (77.8) 7 (58) >0.05 NS
Pathergy test 6 (33.3) 4 (33.3) >0.05 NS
Joint aﬀection 9 (50) 2 (16.7) <0.05 S
Neurological 1 (5.6) 2 (16.7) >0.05 NS
S, signiﬁcant; NS, non signiﬁcant.
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the ESR, CRP and serum levels of high density lipoprotein
(HDL-C) showed no signiﬁcance difference between both sub-
groups Ia and Ib (p> 0.05).
Serum level of VEGF shows highly signiﬁcant difference
between subgroups Ia and Ib being higher in group IaTable 4 Comparison between BD patient’s subgroups as regards a
Groups Mean ± SD Cardiovascular Aﬀection (Group Ia) N= 18
Age (years) 37.4 ±9.75
Disease duration (years) 4.83 ±2.86
BDCAF score 5.33 ±1.68
ESR (mm/h) 50.2 ±33.1
CRP (mg/l) 17.6 ±9.76
Cholesterol (mg/dl) 215 ±42.1
Triglycerides (mg/dl) 104.4 ±12.5
HDL-C (mg/dl) 36.42 ±15.61
LDL-C (mg/dl) 110.5 ±14.3
VEGF (pg/ml) 326 ±113
BDCAF, Behc¸et’s Disease Current Activity Form; CRP, C-reactive prote
lipoprotein cholesterol; VEGF, vascular endothelial growth factor, NS =
* Highly signiﬁcant.(p< 0.01). (Table 4). The highest VEGF levels were
recorded among BD patients with combined cardiac and
vascular lesions (481.7 ± 222.4 pg/ml), followed by those
with isolated cardiac lesions (330.5 ± 141.5 pg/ml), and
lastly patients with isolated vascular lesions (310.4 ± 101.2
pg/ml).ge, disease duration, disease activity, and laboratory data.
No cardiac – vascular aﬀection (Group Ib) N= 12 p-Value
26 ±4.65 <0.001*
2.96 ±1.87 >0.05 NS
2.9 ±1.37 <0.01*
44.67 ±32.81 >0.05 NS
21.75 ±16.83 >0.05 NS
104.58 ±11.76 <0.001*
80.92 ±18.25 <0.001*
39.9 ±10 >0.05 NS
80.75 ±17.61 <0.001*
233 ±84.6 <0.01*
in; HDL-C, high density lipoprotein cholesterol; LDL-C, low density
non signiﬁcant.
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Behc¸et’s Disease Current Activity Form (BDCAF) score
among the subgroup Ia (r= 0.783, p= 0.001) and subgroup
Ib (r= 0.981, p= 0.001).
The difference between the group I and II was statistically
signiﬁcant as regards all echo-cardiographic values except for
inter ventricular septum diameter (IVSD). (Table 5).
The ratio of the mitral inﬂow velocities (E/A ratio) which
indicates left ventricular diastolic dysfunction also was statisti-
cally signiﬁcantly lower in the group I (p< 0.01) (Table 6).
4. Discussion
Behc¸et’s disease (BD) is a multi-systemic, chronic, inﬂamma-
tory disorder of unknown etiology. The incidence and natural
history of cardiac involvement in this disorder are not yet
clearly documented. Cardiovascular manifestations have been
reported in 7–40% of patients in the literature. As nearly 8%
of these will have serious complications during follow-up,
identiﬁcation of the cardiovascular lesions is important [12].
Vascular involvement in BD develops within 10 years of the
initial diagnosis. The ﬁrst 2 years of the disease are the most
critical period. Vascular involvement is more frequent in
men; the reported male:female ratio is 5.6:1 [13]. In our study,
the mean age of the BD patients with cardiovascular involve-
ment was 37.4 ± 9.75 years and the male:female ratio was 8:1.
Although any large or small arteries or veins may be
involved in BD, venous lesions are the predominant vascular
lesions. In the present study the incidence of the vascular
involvement was reported to be 40% (12/30) of the cases. This
result is in accordance to the result of Gu¨l et al [14] who
reported the occurrence of vascular affection in 43% (13/30
patients) that was much higher than the result of Tohme
et al. [15] who reported the occurrence of vascular affection
in 13% only of the studied cases (18/140 patients).
Out of the 12 patients with vascular involvement, 9 (75%)
patients had venous lesions, and 3 (25%) patients had arterial
lesions, but none of our patients had both arterial and venous
lesions. These results partially disagree with Ko et al. [16] who
reported the occurrence of vascular lesions in 51.7% (33/64),
but they showed a relatively equal incidence of venous
(36%), arterial (33%) and combined arterial and venous
(30%) involvement. The causes of this discrepancy may be
related to the ethnic and environmental factors that may mod-
ulate the expression of BD in different geographical areas.Table 5 Comparison between the BD patient and control group as
Parameters Mean ± SD Group I BD Patients (30)
EF% 71.17 ±10.23
Aortic root diameter 3.36 ±0.29
IVSD 0.93 ±0.13
LVED 4.55 ±0.71
LVES 3.28 ±0.703
LAD 3.49 ±0.52
PAP 19.2 ±0.44
RVS 1.7 ±0.44
EF, ejection fraction; IVSD, inter ventricular septum diameter; LVED, left
diameter; LAD, left atrial diameter; PAP, pulmonary artery pressure; RV
* Highly signiﬁcant.Two out of the 3 patients with arterial aneurysm showed
pulmonary artery aneurysms. This ﬁnding comes in accor-
dance with Marzban et al., [8] who reported that pulmonary
artery aneurysm is one of the most common forms of great
artery involvement in BD.
Heart involvement with frank clinical presentation is rare in
BD. It was reported as 1–5% in a case series while it was
16.5% in a registry of Behc¸et autopsy cases in Japan [17].
Sporadic cases of endocarditis, myocarditis, pericarditis, acute
myocardial infarction, aortic aneurysm, ventricular thrombo-
sis, congestive cardiomyopathy, and valvular dysfunction have
been reported [18].
In our study cardiac involvement was detected in eight
patients (26.7%) in the form of endocardial involvement
presented with mitral valve insufﬁciency (4/8), mitral valve
prolapse (1/8), aortic insufﬁciency (1/8) and tricuspid insufﬁ-
ciency (1/8). These results agreed with the results of Gu¨l et al
[14] who detected minimal mitral and tricuspid valve insufﬁ-
ciencies, mitral valve prolapse and mild pulmonary hyperten-
sion in (10/30) 33% of BD patients. Gurgun et al. [18]
detected mitral valve prolapse in 25%, mitral regurgitation
in 40% and aortic valve prolapse in 5% of BD patients [18].
The etiology of valve prolapse in BD can be attributed to
systemic vasculitis and tissue derangement [12].
Also, in the present study we detected the presence of right
ventricular thrombus with right bundle branch block in one
patient. This patient was treated with oral anticoagulant, ste-
roids, azathioprine and cyclosporine therapy with complete
resolution of the thrombus within 2 months. Many cases with
intracardiac thrombosis (ICT) were reported as complication
of BD [19–23] and are usually located in the right side of the
heart, mainly the right ventricle. The reason for predilection
to involve right ventricular is still unclear. Thromboses involv-
ing both ventricles or limited only to the left ventricle have
been also described [14]. Based on autopsy ﬁndings, it looks
that endomyocardial ﬁbrosis plays a role in the ICT develop-
ment in some patients [24], but it is not clear whether they
are secondary to underlying endocarditis or endomyocardial
ﬁbrosis, because in some case reports, a normal underlying
myocardium was described [25].
Coronary artery disease (CAD) is rare in BD. It can be
manifested clinically as myocardial infarction, silent ischemia,
and stable or unstable angina. Coronary occlusion is attrib-
uted to ﬁbrous intimal thickening as a result of local vasculitis
[26]. In agreement with this previous ﬁnding, the coronaryregards the echo-cardio graphic data.
Group II Control (20) p-Value
79.7 ±4.79 <0.001*
3.04 ±0.43 <0.01*
0.94 ±0.14 >0.05 NS
3.92 ±0.27 <0.001*
2.42 ±0.47 <0.001*
2.74 ±0.5 <0.001*
12.2 ±1.99 <0.001*
2.08 ±0.27 <0.001*
ventricular end diastolic diameter; LVES, left ventricular end systolic
S, right ventricular systolic diameter. NS = non signiﬁcant.
Table 6 Comparison between the patient and control group as regards ratio of the mitral inﬂow velocities (E/A ratio).
Group Number (%) Group I BD Patients (30) Group II Control (20) p-Value
Positive (<1) 14 (46.7) 2 (10) <0.01*
Negative 16 (53.3) 18 (90)
E/A ratio, the ratio of the mitral inﬂow velocities.
* Highly signiﬁcant.
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infarction was normal without any atherosclerotic changes.
Left ventricular diastolic dysfunction (E/A mitral Doppler
ﬂow pattern < 1) was detected in 14 (46.7%) of our studied
Behc¸et patients and only 2 (10%) of the controls. This ﬁnding
agreed with the result recorded by Konomidis et al. [27].
VEGF is an endothelial-cell speciﬁc potent angiogenetic
factor and a marker for endothelial dysfunction. VEGF
stimulates inﬂammation, angiogenesis, microvascular
hyper-permeability and endothelium-dependant vasodilatation
as well as endothelium nitrous oxide (NO) production [28].
Endothelial dysfunction due to anti-endothelial cell antibodies
and elevated plasma levels of VEGF leads to disturbance of
microcirculation, increased blood viscosity and abnormal
blood ﬂow [29]. Previous studies reported high plasma levels
of VEGF in Behcet’s syndrome [30], BD with acute thrombosis
[29], and in BD patients with neuro-Behcet’s [31].
In our study the serum levels of VEGF were detected to be
signiﬁcantly higher in BD patients than the controls. On fur-
ther classifying the BD patients according to the presence of
cardiovascular lesions we found that the highest levels were re-
corded among BD patients with combined cardiac and vascu-
lar lesions, followed by those with isolated cardiac lesions, and
lastly patients with isolated vascular lesions. All patients with
cardiovascular lesions were merged into one subgroup (Ia) to
allow reasonable statistical comparison. The subgroup Ia
had signiﬁcantly higher serum levels of VEGF than the sub-
group Ib who had no cardiovascular lesions. The disease activ-
ity score was signiﬁcantly higher among the patients of the
subgroup Ia, this can be explained by the higher incidence of
combination with other disease manifestations.
Our results showed a signiﬁcant positive correlation be-
tween the serum levels of VEGF and the disease activity score
among both BD subgroups Ia and Ib. This ﬁnding occurred in
accordance with the results of Cekmen et al., [32].But, dis-
agreed with Erdem et al., who reported that the serum levels
of VEGF showed no difference between active and inactive
cases of their studied BD [33].
In the present study, BD patients had a high atherogenic
potential as marked by the signiﬁcantly lower HDL, and high-
er LDL, cholesterol and triglycerides concentrations compared
to controls. On further comparison BD patients of the sub-
group Ia had higher LDL, cholesterol and triglycerides con-
centrations compared to patients in the subgroup Ib, but no
statistical difference was detected as regards HDL. In agree-
ment with our ﬁnding some previous studies reported that
BD patients had atherogenic lipid proﬁle [34–36]. But in two
other studies while investigating the risk of atherosclerosis in
patients with BD, blood lipid levels were not signiﬁcantly dif-
ferent from the levels found in the healthy population [37–38].
Recently one study surprisingly reported low blood lipid levels
as a protector against atherosclerosis in BD [39]. This may givea new insight that the inﬂammation, lipid proﬁle and the devel-
opment of atherosclerosis in BD may develop through a differ-
ent mechanism from that associated with other inﬂammatory
conditions.
In conclusion, cardiovascular ﬁndings are not uncommon
in BD, but frank clinical presentation is rare. So, screening
of the cardiovascular system in all patients with BD even if
there is no clinically apparent cardiovascular disease (ECG,
echocardiography, and vascular Doppler with extended
investigations as needed) might unmask silent cardiovascular
lesions for early and proper intervention. High serum levels
of VEGF in BD patients with cardiovascular involvement,
suggests a role for VEGF in the cardiovascular etiopathogen-
esis of the disease, so it can be used as therapeutic targets.
Recently, several anti-VEGF drugs have been approved by
the food and drug administration (FDA) for clinical use [40].
Further clinical trials may be recommended to assess the
efﬁcacy of anti-VEGF drugs as mono-therapy or as part of
combination regimens in BD with cardiovascular lesions.Conﬂict of interest
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